Polona Jaki Mekjavic

Dr. Polona Jaki Mekjavic

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Value in Health Regional Issues
Verified
Journal Article
Open access
PMPolona Jaki Mekjavic
Polona Jaki Mekjavic
VBVilma Jūratė Balčiūnienė
Vilma Jūratė Balčiūnienė
LĆLala Ćeklić
Lala Ćeklić
JEJan Ernest
Jan Ernest
ZJZuzana Jamrichova
Zuzana Jamrichova
MVMiroslav Veith
Miroslav Veith
Despite the significant impact of retinal diseases such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME), there is a limited understanding of how these conditions are managed in Central and Eastern Europe (CEE). To provide a comprehensive overview of the clinical and economic burden of wAMD and DME in CEE and the status quo associated with their management. A narrative literature review was undertaken to identify existing data on wAMD and DME, including epidemiology, economic burden, clinical guidelines, and available and reimbursed treatments. Data were collected from relevant sources such as PubMed, ophthalmology associations, national statistical offices, and government agency websites; practical viewpoints were provided by local ophthalmologists and healthcare economics experts in CEE. Epidemiological data on wAMD and DME are limited in CEE, and intercountry comparison is difficult because of differences in data collection methodologies. There are effective treatment options for wAMD and DME, and international guidelines advocate the use of intravitreal anti-vascular endothelial growth factor injections as first-line therapy. Local expert organizations broadly support these recommendations; nevertheless, no clinical practice guidelines exist on the treatment of wAMD and DME in CEE. Access to and reimbursement of anti-vascular endothelial growth factor agents vary significantly in the region and, as a result, many patients remain untreated or inadequately treated. There is an urgent need for the creation of a wAMD/DME treatment program in CEE to ensure that patients have timely access to the most appropriate treatments.

24 January 2018 in Radiology and Oncology
Verified
Journal Article
Open access
PDF file
AGAna Ursula Gavric
Ana Ursula Gavric
JOJanja Ocvirk
Janja Ocvirk
PMPolona Jaki Mekjavic
Polona Jaki Mekjavic
Background: Mitogen-activated protein kinase kinase (MEK) inhibitor cobimetinib and V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor vemurafenib have significantly improved the prognosis of BRAF-mutated metastatic melanoma. Some ocular symptoms and signs were recently recognized to follow this treatment. The study was aimed to investigate ocular toxicity in patients with metastatic melanoma treated with cobimetinib in combination with vemurafenib. Patients and methods: In the prospective, observational study, patients with BRAF-mutated metastatic melanoma treated with cobimetinib in combination with vemurafenib at the Institute of Oncology Ljubljana were asked to participate. Ophthalmic examination was performed including measurement of visual acuity and intraocular pressure, slit lamp examination, funduscopy (CF), infrared-reflectance (IR) imaging and optical coherence tomography (OCT). Results: Five out of 7 patients noticed changes in vision few days after starting the therapy with cobimetinib. In all patients, small circular lesions, described as MEKAR lesions, were documented in outer retinal layers demonstrated with OCT, IR, and CF. Changes were in the center and/or scattered over the retina almost symmetrical in both eyes in 6 patients, and asymmetrical in one patient, the latter presented also with unilateral anterior uveitis and cystoid macular edema. Conclusions: Multiple bilateral foveal and extrafoveal small retinal lesions in the outer retinal layers develop in patients treated with MEK inhibitor in combination with BRAF inhibitor. Ophthalmologists and oncologists need to be aware of this common, yet relatively benign and often transient ocular side effect to avoid needless intervention, including the discontinuance of a potentially life-prolonging therapy.

1 June 2015 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
DŠDaša Šfiligoj
Daša Šfiligoj
SGSimona Gaberšček
Simona Gaberšček
PMPolona Jaki Mekjavic
Polona Jaki Mekjavic
EPEdvard Pirnat
Edvard Pirnat
KZKatja Zaletel
Katja Zaletel
The first dose of radioiodine (I) does not always cure hyperthyroidism in patients with Graves' disease (GD). Our aim was to evaluate the factors influencing the success of I therapy. We reviewed the medical records of 724 patients who were first diagnosed with GD between 2005 and 2009 and were subsequently treated with I in a fixed-dose manner considering the thyroid volume (TV). TSH, fT(4), and fT(3) were measured. TV was measured by means of ultrasonography. Successful therapy was followed by euthyroidism or hypothyroidism. Out of 724 patients, 656 (90.5%) were successfully (Group 1) and 69 (9.5%) were unsuccessfully (Group 2) treated with the first dose of (131)I. In Group 1, the applied dose of (131)I was lower than that in Group 2 [626±107, 95% confidence interval (CI) 618-634, and 709±140, 95% CI 675-742 MBq, respectively; P<0.001]. At presentation, patients in Group 1 were younger than those in Group 2 (45.5±14.9, 95% CI 44.4-46.6, and 50.1±15.8, 95% CI 46.3-53.9 years, respectively; P=0.031). They had a lower fT(4) (54.9±26.1, 95% CI 52.9-56.9, and 72.1±34.1, 95% CI 63.9-80.3 pmol/l, respectively; P<0.001), a lower fT3 (20.9±8.2, 95% CI 20.3-21.5, and 23.9±8.2, 95% CI 21.9-25.9 pmol/l, respectively; P<0.001), and a smaller TV (21.5±13.2, 95% CI 20.2-22.8, and 35.6±22.3, 95% CI 28.2-42.9 ml, respectively; P<0.001). Before I therapy, patients in Group 1 had a lower fT(3) (9.6±6.0, 95% CI 9.2-10.1, and 11.3±7.6, 95% CI 9.5-13.2 pmol/l, respectively; P=0.038). Successfully treated GD patients were younger, less severely hyperthyroid, and had a smaller TV at presentation. They were also less severely hyperthyroid before I therapy.

1 May 2018 in Frontiers in Medicine
Verified
Journal Article
Open access
PMPolona Jaki Mekjavic
Polona Jaki Mekjavic
Polona Zaletel BendaPolona Zaletel Benda
Polona Zaletel Benda
Objective: The aim of this study is two-fold. First, to evaluate the long-term outcome of anti-vascular endothelial growth factor (anti-VEGF) treatment in a clinical setting using the »treat-and-extend regimen« (TER) in patients with neovascular age-related macular degeneration (nAMD). Second, to determine the proportion of patients treated with anti-VEGF with good visual acuity, i.e. vision sufficient to maintain a high level of independence. Design: We conducted a single center retrospective review of patients with treatment-naive nAMD that were treated with anti-VEGF. Patients were treated with anti-VEGF intravitreal injections according to the »treat-and-extend« (TER) regimen. Patients started treatment with monthly injections of either bevacizumab (1.25 mg/0.05 mL) or ranibizumab (0.5 mg/0.05 mL) until there were no signs present of choroidal neovascularisation (CNV) activity. CNV activity was determined from fundus examination and SD-OCT imaging. Follow-up administration of intravitreal injections was extended by 2-week intervals, up to a total of 14 weeks, provided no signs of CNV activity were detected. In some patients the first treatment was replaced with aflibercept (2 mg/0.05 ml). Participants: On the basis of the inclusion criterion for the study, that patients had to be treated for 5 years, a total of 101 patients were included in the study. In all patients, one eye was treated for a 5-year period, and thus we studied one hundred and one eyes. Measurements: Best corrected visual acuity (VA) was analysed at baseline, and each year during the five-year follow-up. Results: VA improved initially after year one of treatment. VA decreased in the subsequent four years of treatment, but remained significantly higher from year one to year three of the treatment compared to baseline values. Patients with good VA followed a similar trend: the proportion increased in the first year, and thereafter gradually decreased during the course of the 5-year follow up. At year 5 the number of patients with good VA decreased to baseline values. Conclusions: TER with anti-VEGF for nAMD treatment prevents long-term severe visual loss in real-world setting and maintains patients' VA at levels sufficient to ensure independence.

17 May 2022 in Lasers in Medical Science
Verified
Journal Article
Closed access
PDF file
PKPeter Kiraly
Peter Kiraly
JSJaka Smrekar
Jaka Smrekar
PMPolona Jaki Mekjavic
Polona Jaki Mekjavic

19 June 2014 in European Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
AMAdam C. McDonnell
Adam C. McDonnell
OEOla Eiken
Ola Eiken
PMPolona Jaki Mekjavic
Polona Jaki Mekjavic
IMIgor Mekjavic
Igor Mekjavic